quot mother of b cannabinoids b quot the ris

"Mother of Cannabinoids": The Rising Potential of CBG and CBG-A – Cannabis Health News

✦ New
CED Clinical Relevance
#65 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
AnxietyCancerResearchCBDMental Health
Why This Matters
Patients who have not found adequate relief from CBD or THC-based products may soon have access to better-studied CBG formulations targeting anxiety and cognitive symptoms, but those conversations with a clinician should happen before swapping or adding products.
Clinical Summary

Cannabigerol (CBG) and its acidic precursor cannabigerolic acid (CBGA) are gaining serious scientific attention as researchers examine their potential roles in anxiety reduction, memory enhancement, and anti-cancer activity. CBGA is often called the “mother of cannabinoids” because it serves as the biosynthetic precursor from which THC, CBD, and CBC are all derived, making it a foundational compound in the cannabis plant’s chemistry. Early clinical and preclinical data suggest CBG may have a meaningful therapeutic profile distinct from CBD, warranting more rigorous controlled trials to establish dosing, safety, and efficacy across specific conditions.

Dr. Caplan’s Take
“CBG has earned a closer scientific look, and the field needs Phase 2 and Phase 3 trials now rather than another decade of preclinical studies calling results “promising.”
Clinical Perspective

CBG represents an intriguing frontier in cannabinoid therapeutics that warrants closer clinical attention. As the precursor to major cannabinoids like CBD and THC, CBG’s unique pharmacological profile suggests potential applications in anxiety management and cognitive function that differ meaningfully from its downstream metabolites. The emerging preclinical data on anti-cancer properties is noteworthy, though human clinical trials remain limited and necessary before drawing therapeutic conclusions. Clinicians should monitor the evolving evidence base, particularly regarding CBG’s bioavailability and optimal dosing strategies, as patient interest in this cannabinoid continues to grow. Future research examining CBG-A in its raw plant form may reveal additional clinical utility beyond decarboxylated CBG alone.

💬 Join the Conversation

Have a question about how this applies to your situation? Ask Dr. Caplan →

Want to discuss this topic with other patients and caregivers? Join the forum discussion →